用于系统性硬化症临床试验的改良罗德南皮肤评分的标准化。
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.
作者信息
Khanna Dinesh, Furst Daniel E, Clements Philip J, Allanore Yannick, Baron Murray, Czirjak Lazlo, Distler Oliver, Foeldvari Ivan, Kuwana Masataka, Matucci-Cerinic Marco, Mayes Maureen, Medsger Thomas, Merkel Peter A, Pope Janet E, Seibold James R, Steen Virginia, Stevens Wendy, Denton Christopher P
机构信息
University of Michigan Scleroderma Program, Ann Arbor, MI, USA.
UCLA, Los Angeles, CA, USA.
出版信息
J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.
Abstract
The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). This state-of-art review provides a historical perspective of the development of the mRSS, summarizes the performance of mRSS as an outcome measure, provides guidance on assessing mRSS, and makes recommendations for incorporation of the mRSS into clinical trials.
摘要
改良罗德南皮肤评分（mRSS）是一种衡量皮肤厚度的指标，在系统性硬化症（硬皮病）的临床试验中用作主要或次要结局指标。本综述提供了mRSS发展的历史视角，总结了mRSS作为结局指标的表现，提供了评估mRSS的指导，并就将mRSS纳入临床试验提出了建议。
相似文献
1
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.用于系统性硬化症临床试验的改良罗德南皮肤评分的标准化。
J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.
2
Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.评估硬皮病临床试验联合会关于硬皮病改良 Rodnan 皮肤评分评估的培训建议。
Int J Rheum Dis. 2019 Jun;22(6):1036-1040. doi: 10.1111/1756-185X.13523. Epub 2019 Mar 6.
3
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).改良 Rodnan 皮肤评分的最小临床重要差异：硬皮病肺研究（SLS-I 和 SLS-II）的结果。
Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.
4
Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score.使用改良的罗德南皮肤评分法评估时，健康儿童的皮肤评分显著增加。
Rheumatology (Oxford). 2006 Jan;45(1):76-8. doi: 10.1093/rheumatology/kei106. Epub 2005 Sep 20.
5
High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.皮肤硬化症负担高与系统性硬化症和重叠综合征患者严重的器官受累有关。
Rheumatol Int. 2018 Dec;38(12):2279-2288. doi: 10.1007/s00296-018-4156-4. Epub 2018 Sep 11.
6
Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis.欧洲抗风湿病联盟（EUSTAR）标准化培训对系统性硬化症患者改良罗德南皮肤评分准确性的影响。
Int J Rheum Dis. 2019 Jan;22(1):96-102. doi: 10.1111/1756-185X.13433. Epub 2018 Nov 5.
7
Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.硬皮病皮肤疾病评估：硬皮病研究调查人员的实践与观点
J Scleroderma Relat Disord. 2020 Oct;5(3):167-171. doi: 10.1177/2397198320921044. Epub 2020 May 29.
8
9
Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study.皮肤厚度评分作为系统性硬化症器官受累的替代标志物：一项回顾性观察研究。
Arthritis Res Ther. 2019 May 28;21(1):129. doi: 10.1186/s13075-019-1919-6.
10
Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis.用于提高系统性硬化症改良Rodnan皮肤评分可靠性的皮肤模型。
BMC Rheumatol. 2022 Jun 2;6(1):33. doi: 10.1186/s41927-022-00262-2.
引用本文的文献
1
Overlapping Connective Tissue Disease-Polymyositis and Diffuse Systemic Scleroderma: A Case Report.重叠性结缔组织病-多发性肌炎与弥漫性系统性硬化症：一例报告
Clin Med Insights Arthritis Musculoskelet Disord. 2025 Sep 2;18:11795441251370380. doi: 10.1177/11795441251370380. eCollection 2025.
2
Recombinant Human Annexin A5 Ameliorates Localized Scleroderma by Inhibiting the Activation of Fibroblasts and Macrophages.重组人膜联蛋白A5通过抑制成纤维细胞和巨噬细胞的活化改善局限性硬皮病。
Pharmaceutics. 2025 Jul 30;17(8):986. doi: 10.3390/pharmaceutics17080986.
3
Macrovascular Involvement in Systemic Sclerosis: Association Between Carotid Ultrasound Hemodynamics Parameters and Digital Ulcers.系统性硬化症中的大血管受累：颈动脉超声血流动力学参数与指端溃疡之间的关联
Clin Pract. 2025 Aug 18;15(8):152. doi: 10.3390/clinpract15080152.
4
The serum levels of specific autoantibodies in systemic sclerosis predict a more severe skin involvement.系统性硬化症中特定自身抗体的血清水平预示着更严重的皮肤受累。
J Scleroderma Relat Disord. 2025 Jul 28:23971983251357991. doi: 10.1177/23971983251357991.
5
Performance of Ultra-High-Frequency Ultrasound in the Evaluation of Skin Involvement in Systemic Sclerosis: A Cross-Sectional Pilot Study.超高频率超声在系统性硬化症皮肤受累评估中的应用：一项横断面初步研究。
Diagnostics (Basel). 2025 Jun 24;15(13):1600. doi: 10.3390/diagnostics15131600.
6
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.系统性硬化症治疗的新视野：2025年的进展与新兴疗法
RMD Open. 2025 Jul 1;11(3):e005776. doi: 10.1136/rmdopen-2025-005776.
7
The correlation between retinal microvascular changes by optical coherence tomography angiography and nailfold capillaroscopic findings in patients with systemic sclerosis.系统性硬化症患者中光学相干断层扫描血管造影术检测的视网膜微血管变化与甲襞毛细血管镜检查结果之间的相关性
J Rheum Dis. 2025 Jul 1;32(3):198-210. doi: 10.4078/jrd.2024.0124. Epub 2025 Feb 19.
8
Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis.霉酚酸酯治疗系统性硬化症皮肤纤维化的疗效：一项系统评价和荟萃分析。
J Clin Med. 2025 Jun 12;14(12):4187. doi: 10.3390/jcm14124187.
9
Examining the relationship between vascular biomarkers and both microangiopathy and cutaneous fibrosis in systemic sclerosis.研究系统性硬化症中血管生物标志物与微血管病变及皮肤纤维化之间的关系。
J Scleroderma Relat Disord. 2025 Jun 3:23971983251344040. doi: 10.1177/23971983251344040.
10
EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED AT A QUATERNARY HOSPITAL IN THE STATE OF SÃO PAULO.圣保罗州一家四级医院治疗的系统性硬化症患者的流行病学概况。
Acta Ortop Bras. 2025 Jun 2;33(2):e287081. doi: 10.1590/1413-785220253302e287081. eCollection 2025.
本文引用的文献
1
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.托西珠单抗皮下注射治疗系统性硬化症成人患者的安全性和有效性（faSScinate）：一项 2 期、随机、对照试验。
Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.
2
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.弥漫性皮肤系统性硬化症皮肤纤维化改善情况的预测：一项欧洲抗风湿病联盟系统性硬化症注册研究（EUSTAR）分析
Ann Rheum Dis. 2016 Oct;75(10):1743-8. doi: 10.1136/annrheumdis-2015-208024. Epub 2016 Mar 25.
3
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.自身造血干细胞移植与静脉注射环磷酰胺冲击治疗弥漫性皮肤系统性硬化症：一项随机临床试验。
JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368.
4
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.使用 EUSTAR 数据库预测弥漫性皮肤系统性硬皮病患者皮肤纤维化的恶化。
Ann Rheum Dis. 2015 Jun;74(6):1124-31. doi: 10.1136/annrheumdis-2014-205226. Epub 2014 Jun 30.
5
Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.早期弥漫性系统性硬化症皮肤和肌肉骨骼疾病相关指标及对其变化的反应性。
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1731-9. doi: 10.1002/acr.22339.
6
Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis.抗 RNA 聚合酶 III 抗体在系统性硬化症中的流行情况：来自法国队列的新数据及系统评价和荟萃分析。
Arthritis Rheumatol. 2014 Feb;66(2):407-17. doi: 10.1002/art.38219.
7
A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.霉酚酸酯治疗近期起病的进行性弥漫性皮肤系统性硬化症的前瞻性观察研究。
J Rheumatol. 2012 Jun;39(6):1241-7. doi: 10.3899/jrheum.111229. Epub 2012 Apr 1.
8
The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.用于抗中性粒细胞胞浆抗体相关性血管炎临床试验的 OMERACT 核心结局测量集。
J Rheumatol. 2011 Jul;38(7):1480-6. doi: 10.3899/jrheum.110276.
9
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.皮肤厚度进展率：硬皮病弥漫型患者死亡率和早期内脏器官受累的预测指标。
Ann Rheum Dis. 2011 Jan;70(1):104-9. doi: 10.1136/ard.2009.127621. Epub 2010 Aug 2.
10
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.在一项多中心治疗试验中，硬度计测量硬皮病皮肤疾病的有效性、可靠性和可行性。
Arthritis Rheum. 2008 May 15;59(5):699-705. doi: 10.1002/art.23564.
Zotero 插件